Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia

• DOI: 10.1200/jco.19.01892
• Publication Date: 2019-12-09T21:02:07Z
• Authors: Noelle V. Frey; Pamela A. Shaw; Elizabeth O. Hexner; Edward Pequignot; Saar Gill; Selina M. Luger; James K. Mangan; Alison W. Loren; Alexander E. Perl; Shannon L. Maude; Stephan A. Grupp; Nirav N. Shah; Joan Gilmore; Simon F. Lacey; Jos J. Melenhorst; Bruce L. Levine; Carl H. June; David L. Porter
• Keywords: Acute lymphocytic leukemia

The anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel (CTL019) has an 81% response rate in children with relapsed or chemotherapy refractory (r/r) B-cell acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) is a life-threatening treatment-related toxicity that limits the full therapeutic potential adults. We report outcomes for adults r/r ALL treated optimized CTL019 dosing and CRS management strategy.